ACHILLION PHARMACEUTICALS IN's ticker is ACHN and the CUSIP is 00448Q201. A total of 130 filers reported holding ACHILLION PHARMACEUTICALS IN in Q2 2017. The put-call ratio across all filers is 1.19 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $31,017,000 | +91.4% | 5,143,739 | +14.3% | 0.00% | +100.0% |
| Q3 2019 | $16,206,000 | +6.6% | 4,501,614 | -20.7% | 0.00% | 0.0% |
| Q2 2019 | $15,206,000 | -17.1% | 5,673,763 | -8.4% | 0.00% | 0.0% |
| Q1 2019 | $18,337,000 | +131.8% | 6,195,022 | +24.5% | 0.00% | 0.0% |
| Q4 2018 | $7,909,000 | -55.4% | 4,973,977 | +3.3% | 0.00% | 0.0% |
| Q3 2018 | $17,714,000 | +3.8% | 4,813,569 | -20.1% | 0.00% | 0.0% |
| Q2 2018 | $17,061,000 | -22.3% | 6,027,239 | +1.8% | 0.00% | -50.0% |
| Q1 2018 | $21,956,000 | +33.4% | 5,917,865 | +3.6% | 0.00% | +100.0% |
| Q4 2017 | $16,456,000 | -15.9% | 5,714,874 | +31.1% | 0.00% | -50.0% |
| Q3 2017 | $19,576,000 | +7.3% | 4,359,883 | +9.7% | 0.00% | 0.0% |
| Q2 2017 | $18,243,000 | +0.4% | 3,974,429 | -7.9% | 0.00% | 0.0% |
| Q1 2017 | $18,172,000 | -14.1% | 4,317,216 | -15.7% | 0.00% | 0.0% |
| Q4 2016 | $21,153,000 | -28.6% | 5,121,160 | +40.1% | 0.00% | -33.3% |
| Q3 2016 | $29,613,000 | +26.2% | 3,655,437 | +21.5% | 0.00% | 0.0% |
| Q2 2016 | $23,469,000 | -18.4% | 3,008,555 | -19.3% | 0.00% | 0.0% |
| Q1 2016 | $28,778,000 | -35.6% | 3,727,667 | -10.0% | 0.00% | -40.0% |
| Q4 2015 | $44,714,000 | +29.4% | 4,144,011 | -17.1% | 0.01% | +25.0% |
| Q3 2015 | $34,551,000 | -21.6% | 5,000,529 | +0.5% | 0.00% | -20.0% |
| Q2 2015 | $44,085,000 | +19.0% | 4,975,503 | +32.4% | 0.01% | +25.0% |
| Q1 2015 | $37,058,000 | +6.5% | 3,757,813 | +32.4% | 0.00% | +33.3% |
| Q4 2014 | $34,781,000 | +24.1% | 2,838,903 | +1.1% | 0.00% | 0.0% |
| Q3 2014 | $28,025,000 | +136.9% | 2,807,749 | +79.7% | 0.00% | +200.0% |
| Q2 2014 | $11,831,000 | -47.8% | 1,562,527 | -77.3% | 0.00% | -66.7% |
| Q1 2014 | $22,655,000 | -47.8% | 6,885,429 | -23.7% | 0.00% | 0.0% |
| Q4 2013 | $43,394,000 | +242.6% | 9,020,761 | +115.2% | 0.00% | +50.0% |
| Q3 2013 | $12,665,000 | -53.2% | 4,192,500 | +26.7% | 0.00% | -50.0% |
| Q2 2013 | $27,073,000 | – | 3,309,357 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 13,633,220 | $57,396,000 | 7.04% |
| HealthInvest Partners AB | 497,807 | $2,096,000 | 3.21% |
| BVF INC/IL | 3,285,400 | $13,832,000 | 2.35% |
| EMORY UNIVERSITY | 486,438 | $2,048,000 | 1.93% |
| Marcus Capital, LLC | 69,400 | $1,751,000 | 1.63% |
| DAFNA Capital Management LLC | 196,500 | $827,000 | 0.70% |
| Orbimed Advisors | 13,107,200 | $55,181,000 | 0.62% |
| Rock Springs Capital Management LP | 1,500,000 | $6,315,000 | 0.36% |
| Spark Investment Management LLC | 710,100 | $2,989,000 | 0.19% |
| TURNER INVESTMENTS LLC | 65,420 | $275,000 | 0.18% |